Alimera Sciences (NASDAQ:ALIM) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Monday.

According to Zacks, “Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. “

A number of other equities research analysts have also weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $5.00 target price on shares of Alimera Sciences in a report on Wednesday, August 30th. Cowen restated a “buy” rating on shares of Alimera Sciences in a report on Thursday, November 2nd. Finally, ValuEngine upgraded shares of Alimera Sciences from a “strong sell” rating to a “sell” rating in a report on Friday, October 20th. Two analysts have rated the stock with a sell rating and three have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $3.38.

Shares of Alimera Sciences (NASDAQ ALIM) opened at $1.31 on Monday. The company has a current ratio of 4.84, a quick ratio of 4.65 and a debt-to-equity ratio of -0.71. Alimera Sciences has a fifty-two week low of $1.04 and a fifty-two week high of $1.72.

A number of large investors have recently bought and sold shares of the business. JW Asset Management LLC increased its stake in Alimera Sciences by 15.6% in the 2nd quarter. JW Asset Management LLC now owns 966,000 shares of the biopharmaceutical company’s stock valued at $1,343,000 after buying an additional 130,000 shares during the last quarter. Stonepine Capital Management LLC increased its stake in Alimera Sciences by 158.2% in the 3rd quarter. Stonepine Capital Management LLC now owns 477,226 shares of the biopharmaceutical company’s stock valued at $644,000 after buying an additional 292,399 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in Alimera Sciences by 24.3% in the 2nd quarter. PNC Financial Services Group Inc. now owns 180,300 shares of the biopharmaceutical company’s stock valued at $251,000 after buying an additional 35,200 shares during the last quarter. Finally, KCG Holdings Inc. increased its stake in Alimera Sciences by 127.0% in the 1st quarter. KCG Holdings Inc. now owns 78,604 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 43,977 shares during the last quarter. Hedge funds and other institutional investors own 41.85% of the company’s stock.

WARNING: This report was posted by Watch List News and is the property of of Watch List News. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at https://www.watchlistnews.com/alimera-sciences-alim-rating-lowered-to-sell-at-zacks-investment-research/1731864.html.

Alimera Sciences Company Profile

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

Receive News & Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.